Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this clinical study is to determine the response to two different dosage strengths of a topical nitroglycerin gel in patients with Raynaud's Phenomenon. Patient fingers will be monitored for changes in blood flow and skin temperature. Symptoms of pain, tingling and numbness will also be monitored.
| Condition | Intervention | Phase |
|---|---|---|
|
Raynaud's Disease |
Drug: Nitroglycerin |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | Phase II Dose Response Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's Phenomenon |
- Changes in blood flow in the fingers of the non-dominant hand after the induction of constriction of blood vessels by exposure to local cold temperatures. [ Time Frame: 130 minutes ]
- Reduction in skin temperature recovery time and symptoms in the fingers of the non-dominant hand after the induction of constriction of blood vessels by exposure to local cold temperatures. [ Time Frame: 130 minutes ]
- Frequency and severity of adverse events [ Time Frame: 2 weeks ]
| Estimated Enrollment: | 15 |
| Study Start Date: | May 2007 |
| Study Completion Date: | August 2007 |
It is the intention of this protocol to study, in a controlled manner, the response of fingers of patients with Raynaud's phenomenon to two dosage strengths of a fast acting topical formulation of Nitroglycerin, MQX-503. Patients may have moderate to severe primary Raynaud's phenomenon or Raynaud's phenomenon secondary to autoimmune diseases such as scleroderma.
Quantitative changes in blood flow in the fingers of the non-dominant hand will be measured after the clinical induction of constriction of blood vessels by exposure to local cold temperatures. Secondarily, the quantitative reduction in skin temperature recovery time and symptoms of pain, tingling and numbness associated with Raynaud's phenomenon will be evaluated using a patient hand symptom analog assessment score. The frequency and severity of adverse events associated with MQX-503 will be assessed.
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with Raynaud's phenomenon
- Patients who are willing to discontinue any current therapies for Raynaud's phenomenon
Exclusion Criteria:
- The use of any medication containing nitroglycerin or known to interact with nitroglycerin
- Patients with a history of migraine or other severe headaches
- Open skin lesions or skin conditions in the area where medication is to be applied
- Pregnant or nursing women or those wishing to become pregnant.
Contacts and Locations| United States, New York | |
| The Center for Rheumatology | |
| Albany, New York, United States, 12206 | |
| Principal Investigator: | Lee Shapiro, MD | The Center for Rheumatology |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00480753 History of Changes |
| Other Study ID Numbers: | 07-003 |
| Study First Received: | May 29, 2007 |
| Last Updated: | December 18, 2007 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by MediQuest Therapeutics:
|
Raynaud's phenomenon Raynaud's Disease Raynaud's disease secondary to scleroderma Raynaud's phenomenon secondary to autoimmune disease |
Additional relevant MeSH terms:
|
Raynaud Disease Peripheral Vascular Diseases Vascular Diseases Cardiovascular Diseases Nitroglycerin |
Vasodilator Agents Cardiovascular Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 21, 2013